Merck Gains Support for Broader Use of Preventive RSV Treatment

What happened

A European Medicines Agency committee recommended expanding Merck’s Enflonsia use to prevent RSV in certain children up to 24 months old who remain at increased risk of severe disease through their second RSV season. The European Commission will review the recommendation, with a final decision expected within two months.

Confirmed

Global impact / market context

If approved, the broader indication could let Merck offer Enflonsia to eligible children in more situations, potentially increasing treatment demand and revenue. The recommendation is not final authorization, so sales impact depends on the European Commission’s decision and eventual uptake among families and healthcare providers.

Analyst inference

The article describes a regulatory step, not a final approval or a reported financial result. The European Commission’s decision will determine whether Enflonsia can be marketed for this expanded use in the European Union, Iceland, Liechtenstein and Norway; the article gives no sales estimates or market reaction.

Confirmed

What to watch

1. The European Commission’s decision, expected within two months, will establish whether Enflonsia receives marketing authorization for the expanded use across the named European markets. Confirmed
2. The committee recommended treatment for certain children up to 24 months old who remain at increased risk of severe RSV through their second RSV season. Confirmed
3. If authorization follows, uptake among eligible families and healthcare providers will determine whether the broader use translates into additional treatment demand and revenue for Merck. Analyst inference

Evidence

• Original source link unavailable